168 related articles for article (PubMed ID: 26991471)
1. Clinical prognostic value of DNA methylation in hepatoblastoma: Four novel tumor suppressor candidates.
Honda S; Minato M; Suzuki H; Fujiyoshi M; Miyagi H; Haruta M; Kaneko Y; Hatanaka KC; Hiyama E; Kamijo T; Okada T; Taketomi A
Cancer Sci; 2016 Jun; 107(6):812-9. PubMed ID: 26991471
[TBL] [Abstract][Full Text] [Related]
2. A novel risk stratification model based on the Children's Hepatic Tumours International Collaboration-Hepatoblastoma Stratification and deoxyribonucleic acid methylation analysis for hepatoblastoma.
Kondo T; Honda S; Suzuki H; Ito YM; Kawakita I; Okumura K; Ara M; Minato M; Kitagawa N; Tanaka Y; Tanaka M; Shinkai M; Hishiki T; Watanabe K; Ida K; Takatori A; Hiyama E; Taketomi A
Eur J Cancer; 2022 Sep; 172():311-322. PubMed ID: 35816972
[TBL] [Abstract][Full Text] [Related]
3. The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients.
Honda S; Haruta M; Sugawara W; Sasaki F; Ohira M; Matsunaga T; Yamaoka H; Horie H; Ohnuma N; Nakagawara A; Hiyama E; Todo S; Kaneko Y
Int J Cancer; 2008 Sep; 123(5):1117-25. PubMed ID: 18537155
[TBL] [Abstract][Full Text] [Related]
4. MT1G hypermethylation: a potential prognostic marker for hepatoblastoma.
Sakamoto LH; DE Camargo B; Cajaiba M; Soares FA; Vettore AL
Pediatr Res; 2010 Apr; 67(4):387-93. PubMed ID: 20032811
[TBL] [Abstract][Full Text] [Related]
5. RASSF1A methylation indicates a poor prognosis in hepatoblastoma patients.
Honda S; Miyagi H; Suzuki H; Minato M; Haruta M; Kaneko Y; Hatanaka KC; Hiyama E; Kamijo T; Okada T; Taketomi A
Pediatr Surg Int; 2013 Nov; 29(11):1147-52. PubMed ID: 23989600
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
Carrillo-Reixach J; Torrens L; Simon-Coma M; Royo L; Domingo-Sàbat M; Abril-Fornaguera J; Akers N; Sala M; Ragull S; Arnal M; Villalmanzo N; Cairo S; Villanueva A; Kappler R; Garrido M; Guerra L; Sábado C; Guillén G; Mallo M; Piñeyro D; Vázquez-Vitali M; Kuchuk O; Mateos ME; Ramírez G; Santamaría ML; Mozo Y; Soriano A; Grotzer M; Branchereau S; de Andoin NG; López-Ibor B; López-Almaraz R; Salinas JA; Torres B; Hernández F; Uriz JJ; Fabre M; Blanco J; Paris C; Bajčiová V; Laureys G; Masnou H; Clos A; Belendez C; Guettier C; Sumoy L; Planas R; Jordà M; Nonell L; Czauderna P; Morland B; Sia D; Losic B; Buendia MA; Sarrias MR; Llovet JM; Armengol C
J Hepatol; 2020 Aug; 73(2):328-341. PubMed ID: 32240714
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of
Beck A; Trippel F; Wagner A; Joppien S; Felle M; Vokuhl C; Schwarzmayr T; Strom TM; von Schweinitz D; Längst G; Kappler R
Clin Epigenetics; 2018; 10():27. PubMed ID: 29507645
[TBL] [Abstract][Full Text] [Related]
8. Primary malignant epithelial tumors of the liver in children: a study of DNA content and oncogene expression.
Zerbini MC; Sredni ST; Grier H; Cristofani LM; Latorre MR; Hollister KA; Alves VA; Weinberg DS; Perez-Atayde AR
Pediatr Dev Pathol; 1998; 1(4):270-80. PubMed ID: 10463288
[TBL] [Abstract][Full Text] [Related]
9. Low expression of N-myc downstream-regulated gene 2 (NDRG2) correlates with poor prognosis in hepatoblastoma.
Gödeke J; Luxenburger E; Trippel F; Becker K; Häberle B; Müller-Höcker J; von Schweinitz D; Kappler R
Hepatol Int; 2016 Mar; 10(2):370-6. PubMed ID: 26646663
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations.
Regel I; Eichenmüller M; Mahajan UM; Hagl B; Benitz S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
J Cancer Res Clin Oncol; 2020 May; 146(5):1153-1167. PubMed ID: 32189106
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic and prognostic value of SALL4 in hepatoblastoma.
Zhou S; Venkatramani R; Gomulia E; Shillingford N; Wang L
Histopathology; 2016 Nov; 69(5):822-830. PubMed ID: 27252091
[TBL] [Abstract][Full Text] [Related]
12. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
[TBL] [Abstract][Full Text] [Related]
13. Targeting excessive MYCN expression using MLN8237 and JQ1 impairs the growth of hepatoblastoma cells.
Eberherr C; Beck A; Vokuhl C; Becker K; Häberle B; Von Schweinitz D; Kappler R
Int J Oncol; 2019 May; 54(5):1853-1863. PubMed ID: 30864675
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation in Hepatoblastoma-a literature review.
Shen G; Shen H; Zhang J; Yan Q; Liu H
Ital J Pediatr; 2020 Aug; 46(1):113. PubMed ID: 32758256
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of molecular genetic alterations in hepatoblastoma.
von Schweinitz D; Kraus JA; Albrecht S; Koch A; Fuchs J; Pietsch T
Med Pediatr Oncol; 2002 Feb; 38(2):104-8. PubMed ID: 11813174
[TBL] [Abstract][Full Text] [Related]
16. Should children at risk for familial adenomatous polyposis be screened for hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for APC germline mutations?
Aretz S; Koch A; Uhlhaas S; Friedl W; Propping P; von Schweinitz D; Pietsch T
Pediatr Blood Cancer; 2006 Nov; 47(6):811-8. PubMed ID: 16317745
[TBL] [Abstract][Full Text] [Related]
17. Methylation changes in the human IGF2 p3 promoter parallel IGF2 expression in the primary tumor, established cell line, and xenograft of a human hepatoblastoma.
Eriksson T; Frisk T; Gray SG; von Schweinitz D; Pietsch T; Larsson C; Sandstedt B; Ekström TJ
Exp Cell Res; 2001 Oct; 270(1):88-95. PubMed ID: 11597130
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide analysis of allelic imbalances reveals 4q deletions as a poor prognostic factor and MDM4 amplification at 1q32.1 in hepatoblastoma.
Arai Y; Honda S; Haruta M; Kasai F; Fujiwara Y; Ohshima J; Sasaki F; Nakagawara A; Horie H; Yamaoka H; Hiyama E; Kaneko Y
Genes Chromosomes Cancer; 2010 Jul; 49(7):596-609. PubMed ID: 20461752
[TBL] [Abstract][Full Text] [Related]
19. Cytomorphology of hepatoblastoma with histological correlation and role of SALL4 immunocytochemistry in its diagnosis, subtyping, and prognostication.
Nakra T; Roy M; Yadav R; Agarwala S; Jassim M; Khanna G; Das P; Jain D; Mathur SR; Iyer VK
Cancer Cytopathol; 2020 Mar; 128(3):190-200. PubMed ID: 31880869
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation as a key epigenetic player for hepatoblastoma characterization.
Rivas M; Aguiar T; Fernandes G; Lemes R; Caires-Júnior L; Goulart E; Telles-Silva K; Maschietto M; Cypriano M; de Toledo S; Carraro D; da Cunha I; da Costa C; Rosenberg C; Krepischi A
Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101684. PubMed ID: 33852955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
